Norbert Pardi
诺伯特·帕尔迪
PhD
Assistant Professor, Department of Microbiology微生物学系助理教授
👥Biography 个人简介
Norbert Pardi is a leading mRNA vaccine scientist at the University of Pennsylvania, where he works closely with Drew Weissman on nucleoside-modified mRNA and lipid nanoparticle delivery systems. His research has been central to developing LNP-mRNA formulations for cancer immunization, HIV vaccines, and therapeutic applications, directly informing the delivery platforms used in cancer vaccine programs.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Lipid Nanoparticle mRNA Delivery Systems for Cancer Vaccination
Developed and optimized LNP formulations for delivering nucleoside-modified mRNA encoding tumor antigens and neoantigens, demonstrating superior immunogenicity and reduced innate immune activation compared to unmodified mRNA vaccine approaches.
Nucleoside-Modified mRNA Technology
Extended the Karikó-Weissman nucleoside modification platform (pseudouridine substitution) to cancer vaccine antigens, showing that modification reduces immunogenicity of the mRNA backbone while preserving antigen-specific adaptive immune responses critical for cancer vaccines.
mRNA Vaccine Platforms for HIV and Broadly Applicable Immunotherapy
Advanced LNP-mRNA platform to encode HIV antigens and demonstrated that a single intradermal injection of LNP-formulated mRNA can produce high levels of broadly neutralizing antibody responses, informing antigen design for cancer neoantigen vaccines.
Representative Works 代表性著作
Nucleoside-modified mRNA vaccines induce potent T follicular helper-type antibody responses
Immunity (2018)
Demonstrated that LNP-formulated nucleoside-modified mRNA vaccines strongly activate T follicular helper cells and germinal center reactions, critical for durable antibody responses with implications for cancer vaccine design.
mRNA vaccines — a new era in vaccinology
Nature Reviews Drug Discovery (2018)
Comprehensive review of mRNA vaccine technology including LNP delivery, nucleoside modification, self-amplifying mRNA, and oncology applications; one of the most cited reviews in the vaccine field.
Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination
Nature (2017)
Demonstrated that a single dose of LNP-formulated nucleoside-modified mRNA vaccine provides full protection against Zika; established dose optimization principles applied to cancer mRNA vaccine regimens.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
关注 诺伯特·帕尔迪 的研究动态
Follow Norbert Pardi's research updates
留下邮箱，当我们发布与 Norbert Pardi（University of Pennsylvania Perelman School of Medicine）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment